Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambiotech's Bio-Pulsed Exosome for fracture healing is a preclinical-stage extracellular vesicle (EV)-based therapy designed to accelerate bone repair and regeneration. Developed by Ascension Medical Biotechnology (Ambiotech), the therapy utilizes the proprietary Bio-Pulsed technology, which involves a specific activation method to induce stem cells to produce exosomes with enhanced therapeutic gene profiles tailored for bone tissue recovery. While the platform is versatile, this specific application focuses on promoting osteogenesis and supporting the healing of fractures. The therapy is part of a broader pipeline of induced exosomes derived from stem cells, such as SPF chicken embryonic mesenchymal cells, though the specific cell source for the fracture healing program has not been explicitly confirmed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ambiotech Bio-Pulsed Exosome for fracture healing.